Clinical Trial Supplies Industry Overview

The global clinical trial supplies market size was estimated at USD 3.97 billion in 2030 and is anticipated to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030. Increasing volume of clinical trial studies coupled with the growing complexity in conduction of these trials are some of the major factors driving the market growth.

Globally, an increase in the prevalence of chronic diseases and the rapidly aging population are expected to drive the growth of R&D of biologics, which is expected to further propel the demand for efficient clinical supplies and contribute to the growth of the clinical trial supplies industry. Furthermore, an increase in the demand for orphan drugs and high investment in the R&D of rare diseases are also expected to contribute toward the development of biologic drugs. Thus, owing to these factors, this segment is likely to witness significant growth during the forecast period.

Gather more insights about the market drivers, restrains and growth of the Clinical Trial Supplies Market

For instance, in 2022, Novartis invested around USD 10 billion in research and development. It also secured 23 approvals in the European Union, Japan, China, and the U.S. for new drugs and rare diseases. The company is also conducting 44 ongoing phase III programs in India with 17 clinical programs running in rare diseases such as atypical hemolytic uremic syndrome (aHUS), Immune thrombocytopenic purpura (ITP), spinal muscular atrophy (SMA), and Lupus Nephritis.

Direct-to-Patients (DTP) is an upcoming segment in the distribution of clinical trial supplies, which is expected to be the future model of distribution. DTP is one of the emerging models that involves delivering drugs to patients directly to create patient-centric trials. This would facilitate fewer visits to the site and reduce the burden on participants. The COVID-19 outbreak has led to the increased adoption of such a model, to continue clinical trial studies with minimum disruption. In addition, patient retention and a diverse pool of patients worldwide are some of the notable reasons that can be attributed to the high adoption of this model.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The S. donor egg IVF services market size was estimated at USD 398.5 million in 2024 and is projected to grow at a CAGR of 4.4% from 2025 to 2030

• The global electro-medical and electrotherapeutic apparatus market size was estimated at USD 66.2 billion in 2024 and is projected to grow at a CAGR of 6.4% from 2025 to 2030.

Clinical Trial Supplies Market Segmentation

Grand View Research has segmented the global clinical trial supplies market based on clinical phase, product/service, end-use, therapeutic use, and region:

Clinical Trial Supplies Clinical Phase Outlook (Revenue, USD Billion, 2018 - 2030)

• Phase I
• Phase II
• Phase III
• Others

Clinical Trial Supplies Product/Service Outlook (Revenue, USD Billion, 2018 - 2030)

• Manufacturing
• Storage & distribution
  • Cold chain based
  • Non-cold chain based
• Supply chain management

Clinical Trial Supplies End-Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Pharmaceuticals
• Biologics
• Medical device
• Others

Clinical Trial Supplies Therapeutic Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Oncology
• CNS
• Cardiovascular
• Infectious disease
• Metabolic disorders
• Others

Clinical Trial Supplies Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America
  • US             
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Companies profiled:

• Almac Group
• Biocair
• Catalent Inc.
• KLIFO
• Movianto
• PCI Pharma Services
• Sharp Services, LLC
• Thermo Fischer Scientific Inc.
• Marken
• PAREXEL International Corporation

Recent Developments

• In February 2023,Catalent completed a USD 2.2 million expansion of its clinical supply facility in Singapore. This expansion has enlarged the site's footprint to 31,000 square feet, providing room for installing 35 new freezers dedicated to ultra-low temperature (ULT) storage.
• In January 2023,ASLAN Pharmaceuticals and Thermo Fisher Scientific entered into a partnership to manufacture a high concentration formulation of Eblasakimab for upcoming studies. Thermo Fisher Scientific will contribute its expertise in biologic manufacturing and scale-up capacity to oversee a clinical supply of Eblasakimab for the anticipated Phase 3 studies.
• In July 2023,Almac Sciences announced the opening of a custom-built GMP warehouse and dispatch hub at Almac Group’s global headquarters in Craigavon, UK. The facility will support all the manufacturing and lab activities of Active Pharmaceutical Ingredients from development to their commercialization.

Order a free sample PDF of the Clinical Trial Supplies Market Intelligence Study, published by Grand View Research.